Clinical trial
The Effect of Ruboxistaurin on Small Fiber Function
NCT00190970 · Chromaderm, Inc., Industry · Completed
Key facts
| NCT number | NCT00190970 |
|---|---|
| Title | The Effect of Ruboxistaurin on Small Fiber Function |
| Official title | The Effect of Ruboxistaurin Mesylate (LY333531) on Small Fiber Function as Measured by Microvascular Skin Blood Flow, C-Fiber Quantitations in Skin and Quantitative Sensory Testing of Cold and Heat. |
| Lead sponsor | Chromaderm, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetic Neuropathy |
| Intervention type | Drug |
| Interventions | Ruboxistaurin |
| Enrollment | 52 |
| Start date | Oct 1, 2004 |
| Completion | Nov 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 26, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: